xilinmen(603008)

Search documents
喜临门(603008) - 喜临门家具股份有限公司第六届监事会第九次会议决议的公告
2025-08-20 10:00
本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 喜临门家具股份有限公司 第六届监事会第九次会议决议的公告 证券代码:603008 证券简称:喜临门 公告编号:2025-037 (2)2025 年半年度报告的内容和格式符合中国证监会和证券交易所的各项 规定,所包含的信息能从各个方面真实地反映出公司报告期的经营管理和财务状 况等事项; (3)在提出本意见前,没有发现参与 2025 年半年度报告编制和审议的人员 有违反保密规定的行为。 表决结果:同意:3 票;反对:0 票;弃权:0 票。 具体内容详见公司同日在《中国证券报》《上海证券报》《证券时报》《证券 日报》和上海证券交易所网站(www.sse.com.cn)披露的《喜临门家具股份有限 公司 2025 年半年度报告》及摘要。 2、审议通过《2025 年半年度利润分配预案》 一、监事会会议召开情况 喜临门家具股份有限公司(以下简称"公司")于 2025 年 8 月 20 日在公司 3 号会议室以现场方式召开第六届监事会第九次会议。本次会议通知已于 2025 年 8 月 15 日通 ...
喜临门(603008) - 喜临门家具股份有限公司关于2025年半年度利润分配预案的公告
2025-08-20 10:00
证券代码:603008 证券简称:喜临门 公告编号:2025-039 喜临门家具股份有限公司 关于 2025 年半年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 每股分配比例:每股派发现金红利人民币 0.28 元(含税)。 本次利润分配以实施权益分派股权登记日登记的总股本为基数,具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的,拟维持每股分配比例不变,相应调整分配总额,并将另行公告具体调 整情况。 本次利润分配预案尚需提交公司股东大会审议。 一、 利润分配预案内容 本次利润分配预案尚需提交公司股东大会审议。 二、 公司履行的决策程序 (一)董事会会议的召开、审议和表决情况 公 司 2025 年 半 年 度 实 现 归 属 于 上 市 公 司 股 东 净 利 润 为 人 民 币 266,491,172.67 元。截至 2025 年 6 月 30 日,公司母公司报表中期末未分配利 润为人民币 2,487,766,951.73 元。在充分考虑公司盈利情况 ...
喜临门(603008) - 2025 Q2 - 季度财报
2025-08-20 09:50
[Definitions](index=5&type=section&id=Item%201.%20Definitions) This chapter defines key terms and abbreviations used in the report, such as "the Company" referring to Sleemon Furniture Co., Ltd., and "Controlling Shareholder" referring to Zhejiang Huayi Intelligent Manufacturing Co., Ltd - This chapter defines key terms and abbreviations used in the report, such as **"the Company"** referring to Sleemon Furniture Co., Ltd., and **"Controlling Shareholder"** referring to Zhejiang Huayi Intelligent Manufacturing Co., Ltd[16](index=16&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides an overview of Sleemon Furniture Co., Ltd., including its basic information and key financial performance metrics for the first half of 2025 [Company Basic Information](index=6&type=section&id=Company%20Information) This chapter provides basic information about Sleemon Furniture Co., Ltd., including its Chinese and English names, legal representative, contact details, registered address, and information disclosure channels Company Information | Item | Information | | :--- | :--- | | **Company Chinese Name** | 喜临门家具股份有限公司 | | **Stock Abbreviation** | 喜临门 | | **Stock Code** | 603008 | | **Legal Representative** | 陈阿裕 | | **Registered Address** | 浙江省绍兴市越城区灵芝镇二环北路1号 | | **Company Website** | http://www.sleemon.cn/ | [Key Accounting Data and Financial Indicators](index=6&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) In the first half of 2025, the company achieved operating revenue of 4.021 billion CNY, a 1.59% year-on-year increase, with net profit attributable to shareholders rising 14.04% to 266 million CNY. Basic earnings per share increased by 14.29% to 0.72 CNY/share, and net cash flow from operating activities significantly improved despite remaining negative Key Accounting Data for H1 2025 (Unit: CNY) | Key Accounting Data | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 4,020,509,915.07 | 3,957,601,195.25 | 1.59 | | **Net Profit Attributable to Shareholders of Listed Company** | 266,491,172.67 | 233,677,195.79 | 14.04 | | **Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Items)** | 259,560,008.85 | 222,899,255.22 | 16.45 | | **Net Cash Flow from Operating Activities** | -39,624,133.07 | -173,790,428.97 | Not Applicable | | **Total Assets (Period-end)** | 8,642,870,981.43 | 8,904,781,941.06 | -2.94 (Compared to prior year-end) | Key Financial Indicators for H1 2025 | Key Financial Indicators | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Basic Earnings Per Share (CNY/share)** | 0.72 | 0.63 | 14.29 | | **Diluted Earnings Per Share (CNY/share)** | 0.72 | 0.63 | 14.29 | | **Weighted Average Return on Net Assets (%)** | 6.87 | 6.13 | Increased by 0.74 percentage points | | **Weighted Average Return on Net Assets (Excluding Non-recurring Items) (%)** | 6.69 | 5.85 | Increased by 0.84 percentage points | - During the reporting period, the company's non-recurring gains and losses totaled **6.9312 million CNY**, primarily from government subsidies and fair value changes in financial assets[27](index=27&type=chunk) [Management Discussion and Analysis](index=8&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) This section provides management's perspective on the company's industry, business operations, core competencies, and financial performance during the reporting period, along with risk analysis and mitigation strategies [Industry and Main Business Overview](index=8&type=section&id=Description%20of%20the%20Company%27s%20Industry%20and%20Main%20Business%20During%20the%20Reporting%20Period) The company operates in the upholstered furniture manufacturing sector, focusing on mattresses, and despite industry pressures, benefits from consumption upgrades and "trade-in" policies, maintaining its leadership with extensive production bases and stores while investing in AI technology - The company operates in the **furniture manufacturing industry (C21)**, specifically the upholstered furniture sector, with products primarily including mattresses, upholstered beds, and sofas[30](index=30&type=chunk) - In the first half of 2025, China's furniture industry continued to exhibit characteristics of **"overall pressure with structural optimization"**, with revenue for large-scale furniture manufacturers decreasing by **4.9% year-on-year**, though the decline narrowed compared to Q1, showing marginal improvement[32](index=32&type=chunk) - The company is a leader in China's mattress industry, boasting **eight domestic production bases**, one overseas base in Thailand, **over 5,000 offline stores**, and continuous investment in AI smart sleep product R&D[36](index=36&type=chunk) - The company's sales models include **own-brand retail** (online and offline), **own-brand engineering channels** (hotels, apartments), and **OEM business channels** (manufacturing for leading domestic and international brands)[55](index=55&type=chunk)[56](index=56&type=chunk)[57](index=57&type=chunk) [Discussion and Analysis of Operations](index=13&type=section&id=Discussion%20and%20Analysis%20of%20Operations) In H1 2025, designated as "AI Year One," the company strategically transformed into a technology-driven sleep solution provider, achieving robust growth by optimizing online and offline retail, upgrading "Net-Sleep Formaldehyde Removal Technology," expanding its "aise Baobao" AI product matrix, and integrating AI into internal operations for efficiency gains - The company designated **2025 as "AI Year One"**, committing to transform from a traditional furniture manufacturer into a technology-driven sleep solution provider[60](index=60&type=chunk) - In technological innovation, the company upgraded its **"Net-Sleep Formaldehyde Removal Technology"**, launched new Net-Sleep M series and zero-glue mattresses; the AI product matrix continues to improve with the addition of **aise Baobao Cloud Enjoy series** and **Sleemon AI Net-Sleep E series** product lines[63](index=63&type=chunk) - The company deepened industry-academia-research collaboration, co-establishing a **Smart Sleep Technology Joint Research Center with Tsinghua University**, and forming an exclusive strategic partnership with **Strong Brain Technology** to launch co-branded AI mattresses and jointly develop brain-computer interface-based sleep solutions[63](index=63&type=chunk) - AI technology has been applied in various scenarios, including human resources, quality inspection, intelligent customer service, and in-store smart bed selection systems, effectively **improving operational efficiency and service conversion rates**[64](index=64&type=chunk) [Analysis of Core Competencies](index=14&type=section&id=Analysis%20of%20Core%20Competencies%20During%20the%20Reporting%20Period) The company's core competencies remained stable, highlighted by strong design and R&D, a leading brand position as "China's first mattress stock," extensive online and offline marketing networks, efficient manufacturing and digitalized supply chains, and robust quality control systems - **Design and R&D Advantage**: The company is a national high-tech enterprise, possessing provincial-level key enterprise research institutes and academician expert workstations, forming a virtuous cycle of independent R&D complemented by industry-academia-research collaboration[66](index=66&type=chunk)[67](index=67&type=chunk) - **Brand Advantage**: Known as "China's first mattress stock," the company has built a pyramid-shaped brand matrix centered on its main brand "Sleemon" and high-end sofa brands "Chateaux" and "M&D," continuously reinforcing its brand positioning of "spinal protection" and "deep quality sleep"[68](index=68&type=chunk)[69](index=69&type=chunk) - **Marketing Network Advantage**: A comprehensive multi-channel marketing network has been established, with **over 5,000 offline exclusive stores** and full coverage across mainstream e-commerce platforms like Tmall, JD.com, and Douyin[70](index=70&type=chunk) - **Manufacturing and Supply Chain Advantage**: The company operates **eight domestic production bases**, achieving full coverage across China, and an overseas production base in Thailand, integrating CRM, SAP, MES, and other systems to streamline order-to-production processes for efficient and intelligent supply chain management[72](index=72&type=chunk) - **Quality Control Advantage**: The company was among the first to pass the **ISO9001, ISO14001, ISO45001 "three-in-one" management system certification**, and has served as a primary drafting unit for multiple national and industry standards[73](index=73&type=chunk)[74](index=74&type=chunk) [Analysis of Main Operating Performance](index=16&type=section&id=Main%20Operating%20Performance%20During%20the%20Reporting%20Period) During the reporting period, the company's main business financial indicators remained stable, with sales expenses increasing by 8.42% while management, financial, and R&D expenses decreased; significant increases in prepayments, construction in progress, notes payable, and long-term borrowings were noted, alongside strategic investments in Milan Image and new sales subsidiaries Financial Statement Item Variation Analysis | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 4,020,509,915.07 | 3,957,601,195.25 | 1.59 | | **Selling Expenses** | 833,673,502.19 | 768,947,186.99 | 8.42 | | **Administrative Expenses** | 208,718,414.85 | 222,087,357.78 | -6.02 | | **Financial Expenses** | 13,403,476.65 | 17,418,988.01 | -23.05 | | **R&D Expenses** | 82,333,831.16 | 90,105,586.15 | -8.63 | Analysis of Asset and Liability Status Changes | Item Name | Current Period End Amount (CNY) | Prior Period End Amount (CNY) | Change (%) | Primary Reason | | :--- | :--- | :--- | :--- | :--- | | **Prepayments** | 183,832,686.93 | 98,580,621.33 | 86.48 | Increase in prepaid material costs, brand promotion fees, etc | | **Construction in Progress** | 126,296,504.20 | 47,025,497.41 | 168.57 | Factory intelligent transformation, Jiangxi factory phase II construction, etc | | **Notes Payable** | 1,006,389,191.34 | 494,047,735.17 | 103.70 | Increase in settlement by notes | | **Accounts Payable** | 978,153,322.07 | 1,713,925,134.40 | -42.93 | Payment for goods, equipment | | **Long-term Borrowings** | 694,414,900.00 | 261,265,558.33 | 165.79 | Increase in borrowings | - During the reporting period, the company acquired a **30% equity stake** in Jiaxing Milan Image Furniture Co., Ltd. for **97.5 million CNY**, increasing its shareholding from 51% to 81%, aiming to strengthen its sofa product category and overseas business[80](index=80&type=chunk)[89](index=89&type=chunk) [Risk Analysis and Response](index=22&type=section&id=Potential%20Risks%20and%20Countermeasures) The company faces risks from raw material price fluctuations, market competition, demand volatility, international trade friction, operational management, and brand management, addressed through diversified procurement, enhanced competitiveness, market monitoring, adjusted overseas layouts, improved internal controls, and brand protection - The company identified six major risks: **raw material price fluctuations, intensified market competition, market demand volatility, international trade friction, operational management risks, and brand operation and management risks**[91](index=91&type=chunk)[92](index=92&type=chunk)[94](index=94&type=chunk)[96](index=96&type=chunk)[97](index=97&type=chunk) - Countermeasures include: managing raw material costs through centralized procurement and price locking; leveraging brand and channel advantages to capture market share; establishing a sensitive market monitoring system to respond to demand changes; adjusting overseas factory layouts to mitigate trade friction; improving internal organizational structure and risk control systems; and establishing dedicated departments for brand maintenance and crisis public relations[91](index=91&type=chunk)[92](index=92&type=chunk)[93](index=93&type=chunk)[95](index=95&type=chunk)[96](index=96&type=chunk)[97](index=97&type=chunk) [Corporate Governance, Environment, and Society](index=24&type=section&id=Item%204.%20Corporate%20Governance%2C%20Environment%2C%20and%20Society) This section covers the company's profit distribution plan, adjustments to its equity incentive plan, and the proposed cancellation of employee stock ownership plan shares due to unfulfilled performance targets [Profit Distribution Plan](index=24&type=section&id=Profit%20Distribution%20or%20Capital%20Reserve%20Conversion%20Plan) The board approved a H1 2025 profit distribution plan to pay a cash dividend of 2.80 CNY (tax inclusive) per 10 shares, totaling approximately 104 million CNY, representing 39.03% of half-year net profit attributable to the parent company, pending shareholder approval H1 2025 Profit Distribution Plan | Distribution/Conversion Item | Plan | | :--- | :--- | | **Number of Bonus Shares per 10 Shares** | 0 shares | | **Dividend per 10 Shares (tax inclusive)** | 2.80 CNY | | **Number of Shares Converted from Capital Reserve per 10 Shares** | 0 shares | | **Total Proposed Cash Dividend (tax inclusive)** | 104,003,614.40 CNY | | **Percentage of Half-Year Net Profit Attributable to Parent Company** | 39.03% | [Equity Incentive and Employee Stock Ownership Plans](index=24&type=section&id=Company%20Equity%20Incentive%20Plan%2C%20Employee%20Stock%20Ownership%20Plan) During the reporting period, the company adjusted and partially canceled its 2021 stock option incentive plan due to unachieved 2024 performance targets, leading to the cancellation of 872,820 stock options and a proposal to repurchase and cancel 3,149,045 unvested shares from the 2021 employee stock ownership plan - Due to the company's failure to meet its 2024 performance targets, the third exercise period conditions for the 2021 stock option incentive plan were not met, and the company **canceled all remaining 872,820 stock options** on May 29, 2025[103](index=103&type=chunk)[455](index=455&type=chunk) - As performance targets for 2022-2024 were not met, none of the three vesting periods for the 2021 employee stock ownership plan were achieved; the company proposes to **repurchase and cancel all remaining 3,149,045 unvested shares** from the plan at a price of **23.65 CNY/share**[105](index=105&type=chunk)[106](index=106&type=chunk) [Significant Matters](index=28&type=section&id=Item%205.%20Significant%20Matters) This section details the fulfillment of commitments, significant related-party transactions, and major guarantees during the reporting period [Fulfillment of Commitments](index=28&type=section&id=Fulfillment%20of%20Commitments) During and continuing into the reporting period, the company's actual controller, shareholders, and related parties strictly fulfilled all commitments made during major asset restructurings, initial public offerings, and equity incentives, including those concerning avoiding horizontal competition, regulating related-party transactions, and share lock-ups, with no breaches reported - The company's controlling shareholder, actual controller, and related parties strictly fulfilled all commitments during the reporting period regarding **avoiding horizontal competition, regulating related-party transactions, and share lock-ups**[109](index=109&type=chunk)[110](index=110&type=chunk)[111](index=111&type=chunk) [Significant Related-Party Transactions](index=31&type=section&id=Significant%20Related-Party%20Transactions) The company projected its 2025 annual routine related-party transactions and is currently preparing and refining materials for a proposed non-public issuance of A-shares to Anhui Xinhong Equity Investment Co., Ltd., a wholly-owned subsidiary of the controlling shareholder, which constitutes a related-party transaction - The company approved the **"Proposal on Estimated Routine Related-Party Transactions for 2025"** in April 2025[113](index=113&type=chunk) - The company plans to privately issue **66,354,410 A-shares** to Anhui Xinhong Equity Investment Co., Ltd., a wholly-owned subsidiary of the controlling shareholder, which constitutes a related-party transaction and is currently in progress[115](index=115&type=chunk)[116](index=116&type=chunk) [Significant Guarantees](index=33&type=section&id=Significant%20Guarantees) During the reporting period, all external guarantees were provided to wholly-owned subsidiaries to support their operations and business expansion; as of the period-end, the total guarantee balance for subsidiaries was 221 million CNY, representing 5.85% of the company's net assets, with no irregular guarantees Company Guarantee Total (Unit: Ten Thousand CNY) | Item | Amount | | :--- | :--- | | **Total Guarantees Provided to Subsidiaries During the Reporting Period** | 21,750.00 | | **Total Guarantee Balance for Subsidiaries at Period-End (B)** | 22,060.00 | | **Total Guarantees (A+B)** | 22,060.00 | | **Percentage of Total Guarantees to Company's Net Assets (%)** | 5.85 | [Share Changes and Shareholder Information](index=34&type=section&id=Item%206.%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital due to share repurchases and cancellations, along with an overview of its shareholder structure, including the top ten shareholders and their respective holdings [Share Capital Changes](index=34&type=section&id=Share%20Capital%20Changes) During the reporting period, the company's total share capital changed due to share repurchases and cancellations, with 7,550,400 shares repurchased and canceled in May 2025, reducing the total share capital from 378,991,880 shares to 371,441,480 shares - The company completed share repurchases and cancellations in May 2025, resulting in a reduction of **7,550,400 shares** in its total share capital[122](index=122&type=chunk) Total Share Capital Changes | Item | Quantity Before Change (Shares) | Current Change (Shares) | Quantity After Change (Shares) | | :--- | :--- | :--- | :--- | | **Total Shares** | 378,991,880 | -7,550,400 | 371,441,480 | [Shareholder Information](index=35&type=section&id=Shareholder%20Information) As of the end of the reporting period, the company had 15,699 common shareholders, with the controlling shareholder, Zhejiang Huayi Intelligent Manufacturing Co., Ltd., holding 22.83%, and the actual controller, Chen Ayu, along with his concerted parties, holding a combined 36.05% - As of the end of the reporting period, the company had a total of **15,699 common shareholders**[124](index=124&type=chunk) Top Three Shareholders' Holdings | Shareholder Name | Shares Held at Period-End (Shares) | Percentage (%) | | :--- | :--- | :--- | | **Zhejiang Huayi Intelligent Manufacturing Co., Ltd.** | 84,799,659 | 22.83 | | **Shaoxing Yuecheng Huahan Equity Investment Partnership (Limited Partnership)** | 36,807,950 | 9.91 | | **National Social Security Fund 413 Portfolio** | 10,897,147 | 2.93 | - Controlling shareholder Zhejiang Huayi Intelligent Manufacturing Co., Ltd., Shaoxing Yuecheng Huahan Equity Investment Partnership (Limited Partnership), actual controller Chen Ayu, and Shaanxi Guotou · Jinyu No. 201 Trust Plan are **parties acting in concert**[127](index=127&type=chunk) [Bond-Related Information](index=38&type=section&id=Item%207.%20Bond-Related%20Information) This section confirms that the company had no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds during the reporting period [Corporate Bonds and Convertible Corporate Bonds](index=38&type=section&id=Corporate%20Bonds%20and%20Convertible%20Corporate%20Bonds) During the reporting period, the company had no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds - The company had **no corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds** during this reporting period[131](index=131&type=chunk) [Financial Report](index=39&type=section&id=Item%208.%20Financial%20Report) This section presents the company's unaudited consolidated and parent company financial statements for the first half of 2025, including the balance sheet, income statement, cash flow statement, and statement of changes in owners' equity [Financial Statements](index=39&type=section&id=Financial%20Statements) This chapter provides the company's unaudited consolidated and parent company financial statements for the first half of 2025, including the balance sheet, income statement, cash flow statement, and statement of changes in owners' equity - The financial report in this semi-annual report is **unaudited**[7](index=7&type=chunk)[133](index=133&type=chunk) Key Items from Consolidated Balance Sheet (June 30, 2025) (Unit: CNY) | Item | Period-End Balance (CNY) | Prior Year-End Balance (CNY) | | :--- | :--- | :--- | | **Total Assets** | 8,642,870,981.43 | 8,904,781,941.06 | | **Total Liabilities** | 4,823,048,333.35 | 4,983,821,714.47 | | **Total Owners' Equity Attributable to Parent Company** | 3,772,795,790.72 | 3,767,736,426.88 | Key Items from Consolidated Income Statement (Jan-Jun 2025) (Unit: CNY) | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | **Total Operating Revenue** | 4,020,509,915.07 | 3,957,601,195.25 | | **Operating Profit** | 299,604,165.85 | 286,300,305.51 | | **Total Profit** | 297,144,153.02 | 276,020,944.13 | | **Net Profit** | 261,653,850.49 | 235,881,318.19 | | **Net Profit Attributable to Parent Company Shareholders** | 266,491,172.67 | 233,677,195.79 | Key Items from Consolidated Cash Flow Statement (Jan-Jun 2025) (Unit: CNY) | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | -39,624,133.07 | -173,790,428.97 | | **Net Cash Flow from Investing Activities** | -234,195,718.43 | -39,527,543.50 | | **Net Cash Flow from Financing Activities** | -211,767,908.96 | 12,724,612.36 | | **Net Increase in Cash and Cash Equivalents** | -485,587,760.46 | -200,593,360.11 | [Notes to Financial Statements](index=57&type=section&id=Notes%20to%20Financial%20Statements) This chapter details the basis of financial statement preparation, accounting standards followed, significant accounting policies and estimates, and provides comprehensive notes on major consolidated financial statement items, related-party relationships and transactions, share-based payments, contingent liabilities, and post-balance sheet events - The financial statements are prepared on a **going concern basis** and comply with the requirements of **Enterprise Accounting Standards**[160](index=160&type=chunk)[163](index=163&type=chunk) - The company's principle for revenue recognition is to recognize revenue when the customer obtains control of the related goods or services; for domestic sales, revenue is recognized upon product delivery to the buyer, and for export sales, upon customs declaration and receipt of the bill of lading[221](index=221&type=chunk)[222](index=222&type=chunk) - As of the period-end, the total book value of assets with restricted ownership or use rights amounted to **1.14 billion CNY**, primarily comprising monetary funds, fixed assets, and intangible assets used for secured borrowings and issuing bank acceptance bills[332](index=332&type=chunk)
喜临门(603008) - 喜临门家具股份有限公司第六届董事会第九次会议决议的公告
2025-08-20 09:45
证券代码:603008 证券简称:喜临门 公告编号:2025-036 第六届董事会第九次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 喜临门家具股份有限公司(以下简称"公司")于 2025 年 8 月 20 日在公司 国际会议室以现场表决的方式召开第六届董事会第九次会议。本次会议通知已 于 2025 年 8 月 15 日通过电子邮件、传真、电话方式送达全体董事。 本次会议由董事长陈阿裕先生召集和主持,会议应参加董事 9 名,实际参 加会议董事 9 名。本次会议通过书面记名投票的方式进行表决,会议的召集、 召开和表决程序符合《公司法》和《公司章程》的规定,会议合法有效。 二、董事会会议审议情况 1、审议通过《2025 年半年度报告及摘要》 表决结果:同意:9 票;反对:0 票;弃权:0 票。 本议案已经公司第六届董事会审计委员会 2025 年第五次会议审议通过,并 同意提交公司董事会审议。 喜临门家具股份有限公司 报告》 表决结果:同意:9 票;反对:0 票;弃权:0 票。 具体内容详见 ...
喜临门(603008.SH)发布上半年业绩,归母净利润2.66亿元,增长14.04%
Zheng Quan Zhi Xing· 2025-08-20 09:40
(原标题:喜临门(603008.SH)发布上半年业绩,归母净利润2.66亿元,增长14.04%) 智通财经APP讯,喜临门(603008.SH)发布2025年半年度报告,该公司营业收入为40.21亿元,同比增长 1.59%。归属于上市公司股东的净利润为2.66亿元,同比增长14.04%。归属于上市公司股东的扣除非经 常性损益的净利润为2.6亿元,同比增长16.45%。基本每股收益为0.72元。 ...
喜临门(603008.SH):上半年净利润2.66亿元,同比增长14.04%
Ge Long Hui A P P· 2025-08-20 09:29
Core Viewpoint - The company reported a revenue of 4.021 billion RMB for the first half of 2025, reflecting a year-on-year growth of 1.59% [1] - The net profit attributable to shareholders reached 266 million RMB, marking a year-on-year increase of 14.04% [1] - The net profit after deducting non-recurring gains and losses was 259 million RMB, showing a year-on-year growth of 16.45% [1] - Basic earnings per share were reported at 0.72 RMB [1] - The company plans to distribute a cash dividend of 2.80 RMB (including tax) for every 10 shares to all shareholders [1] Financial Performance - Revenue: 4.021 billion RMB, up 1.59% year-on-year [1] - Net Profit: 266 million RMB, up 14.04% year-on-year [1] - Net Profit (excluding non-recurring items): 259 million RMB, up 16.45% year-on-year [1] - Basic Earnings per Share: 0.72 RMB [1] Dividend Distribution - Proposed cash dividend: 2.80 RMB per 10 shares (including tax) [1]
踏准脑机接口政策 喜临门AI睡眠弯道超车
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-08-20 05:39
Group 1 - The Ministry of Industry and Information Technology and six other departments have jointly issued implementation opinions to promote the innovation and development of the brain-computer interface (BCI) industry, aiming for breakthroughs in key technologies by 2027 and establishing an advanced technical, industrial, and standard system [1] - The introduction of this policy is seen as a significant milestone, officially recognizing BCI as an independent strategic emerging industry, which will accelerate the practical application and promotion of BCI technology in core areas such as medical rehabilitation and intelligent interaction [1][4] - The BCI technology in China is developing along two parallel paths: invasive (requiring surgical implantation) and non-invasive (collecting signals from the scalp), with sleep health emerging as a key application area for non-invasive technology [1] Group 2 - A strategic partnership has been formed between sleep technology company Xilinmen and non-invasive BCI technology firm Qiangnao Technology to explore multi-space sleep solutions based on BCI technology, creating an intelligent sleep ecosystem centered around "AI companionship" [1][2] - The world's first AI mattress incorporating BCI technology, "Baobao·BrainCo," has been launched, which monitors and analyzes users' brainwave signals in real-time to provide personalized sleep optimization solutions, marking a significant innovation in technology application [2] Group 3 - Despite the industry excitement, BCI development faces significant challenges, including the need for improved accuracy and reliability in brain signal decoding and the integration of multi-modal information from the brain, body, and environment [3] - The global BCI market is projected to reach $400 billion, but actual revenue for the industry may not exceed $1.5 billion by 2035, indicating that the BCI industry is still in its early development stage and far from commercial maturity [3] - The core competition in the BCI field lies not in market speculation but in the continuous technical challenges in laboratories and the ability to translate technology into affordable, safe, and user-centric products [4]
前瞻布局、政策开闸,AI喜临门站上脑机接口风口
Zhong Guo Jin Rong Xin Xi Wang· 2025-08-19 08:02
然而,技术成熟度、用户隐私保护、数据安全以及如何建立普适且高效的脑电解码模型,仍是产业规模 化前必须跨越的障碍。未来脑机接口将如何更深入、更可靠地服务于人,提升生活品质,值得你我共同 关注与期待。 在不久前结束的2025世界机器人大赛——BCI脑控机器人大赛现场,参会者只需将一个"帽子"扣在头 上,就能通过意念操控屏幕上的光标或指挥机械臂完成复杂动作。无独有偶,2025世界人工智能大会 上,一名视障者头戴轻薄脑机接口设备,同样凭意念操控机械臂完成毛线编织……这些直观的演示,不 仅展示了技术可行性,更突显医院非侵入式方案在安全性和用户体验上的独特优势,为政策导向提供了 现实注脚。 在今年7月喜临门与强脑科技独家战略合作签约会上,双方发布全球首款引入脑机脑电技术的AI床垫"宝 褓·BrainCo",通过脑波级睡眠优化直接将行业技术延伸至神经科学领域。据喜临门相关负责人透露, 未来双方的合作将进一步突破睡眠体验的空间限制,加快构建以"AI陪伴"为核心的智能睡眠生态,直 至"今夜无人失眠"美好愿景实现。 工信部等七部门7月印发《关于推动脑机接口产业创新发展的实施意见》,明确我国脑机接口技术发展 目标,提出到2027年 ...
睡眠领域的脑机接口样本,AI喜临门率先探路
Quan Jing Wang· 2025-08-18 07:03
上周,工信部等七部门印发《关于推动脑机接口产业创新发展的实施意见》,明确我国脑机接口技术发 展目标,提出到2027年,脑机接口关键技术取得突破,初步建立先进的技术体系、产业体系和标准体系 并旗帜鲜明地支持"非植入设备量产迭代"。 当马斯克的Neuralink将芯片植入渐冻症患者大脑时,中国科学家正将脑机接口技术带进日常生活。 在不久前结束的2025世界机器人大赛——BCI脑控机器人大赛现场,参会者只需将一个"帽子"扣在头 上,就能通过意念操控屏幕上的光标或指挥机械臂完成复杂动作。无独有偶,2025世界人工智能大会 上,一名视障者头戴轻薄脑机接口设备,同样凭意念操控机械臂完成毛线编织……这些直观的演示,不 仅展示了技术可行性,更突显医院非侵入式方案在安全性和用户体验上的独特优势,为政策导向提供了 现实注脚。 民生证券研报指出,应重视脑机接口研发进程关键拐点,目前标杆企业技术落地预期明确,整体行业有 望从早期阶段逐渐步入高速成长期,建议关注海外映射/有自主研发布局/有落地场景的相关企业。 其中 非侵入式脑机接口技术领军企业强脑科技成为典型代表。 业内人士认为,这一政策导向的深层逻辑在于,相比尚处探索阶段、风险与伦 ...
禾元生物“双喜临门”背后:19年无盈利,奥福民能否扛起“救命稻草”?
Sou Hu Cai Jing· 2025-08-18 00:20
2025年7月,武汉禾元生物科技股份有限公司(以下简称"禾元生物")迎来历史性时刻:核心产品重组 人白蛋白注射液(水稻,商品名"奥福民")正式获批上市,同时科创板IPO注册生效。这家深耕植物源 生物制药19年的企业,凭借"全球首个水稻来源重组人白蛋白"的技术突破,成为资本市场与医药行业的 焦点。然而,光环之下,禾元生物正面临一场关乎生存的硬仗——在无成熟产品销售、连续六年累计亏 损超8亿元的背景下,如何将技术里程碑转化为可持续的商业回报? 从实验室到临床的"黄金救命药"替代者 人血清白蛋白被誉为"黄金救命药",在治疗失血性休克、肝硬化腹水等危重症中不可替代。然而,我国 白蛋白市场长期依赖进口血浆提取制品,供需矛盾尖锐。药智数据显示,2024年全国人血白蛋白批签发 5470批次,进口产品占比近70%,血浆采集量不足导致医院"一药难求"现象频发。 禾元生物的奥福民以水稻胚乳为生物反应器,通过基因编辑技术实现重组人白蛋白的规模化生产。这一 路线突破了传统血浆提取的原料限制,且植物细胞生产过程无哺乳动物病原体风险,安全性优势显著。 2024年11月,公司披露III期临床结果:在肝硬化低白蛋白血症患者中,20g/天剂量 ...